We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+33.34%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$511M
AUM Growth
+$93.5M
Cap. Flow
+$56.7M
Cap. Flow %
11.08%
Top 10 Hldgs %
80.15%
Holding
29
New
13
Increased
1
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
LONA
LeonaBio Inc
LONA
+$25.4M
2
IMV
IMV Inc. Common Shares
IMV
+$18M
3
ALXO icon
ALX Oncology
ALXO
+$11.8M
4
MTCR
Metacrine, Inc. Common Stock
MTCR
+$11.7M
5
COGT icon
Cogent Biosciences
COGT
+$11.4M

Top Sells

Rank Stock Value
1
VXRT
Vaxart
VXRT
+$24.5M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$17.4M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$11.4M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$8.55M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$7.83M

Sector Composition

Rank Sector Weight
1 Healthcare 72.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
1
DELISTED
Trillium Therapeutics Inc.
TRIL
$102M 20.03%
7,204,577
+414,577
+6% +$4.13M
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$81.4M 15.92%
4,016,873
– –
ALT icon
3
Altimmune
ALT
$552M
$59.4M 11.62%
4,500,000
– –
LONA
4
LeonaBio Inc
LONA
$66.3M
$28.1M 5.5%
+152,162
New +$25.4M
SURF
5
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$26.8M 5.23%
3,877,895
– –
KROS icon
6
Keros Therapeutics
KROS
$199M
$25.9M 5.07%
672,306
– –
RLMD icon
7
Relmada Therapeutics
RLMD
$557M
$25.1M 4.92%
668,440
– –
CRDF icon
8
Cardiff Oncology
CRDF
$66.5M
$18M 3.53%
+1,271,985
New +$8.4M
IMV
9
DELISTED
IMV Inc. Common Shares
IMV
$17.8M 3.47%
+400,000
New +$18M
KURA icon
10
Kura Oncology
KURA
$800M
$17.6M 3.45%
575,000
– –
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$15.3M 3%
1,192,883
-238,752
-17% -$2.06M
CLDX icon
12
Celldex Therapeutics
CLDX
$2.99B
$11.9M 2.32%
+800,000
New +$9.37M
MTCR
13
DELISTED
Metacrine, Inc. Common Stock
MTCR
$11.7M 2.28%
+1,143,673
New +$11.7M
ALXO icon
14
ALX Oncology
ALXO
$261M
$11.3M 2.21%
+300,000
New +$11.8M
COGT icon
15
Cogent Biosciences
COGT
$6.65B
$10.2M 1.99%
+1,088,818
New +$11.4M
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.69B
$9.23M 1.81%
625,710
– –
FSDC
17
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$5.6M 1.1%
+500,000
New +$5.35M
TNGX icon
18
Tango Therapeutics
TNGX
$4.43B
$5.18M 1.01%
+500,000
New +$5.11M
TSHA icon
19
Taysha Gene Therapies
TSHA
$1.68B
$2.6M 0.51%
+107,982
New +$2.54M
GRTX
20
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$467K 0.09%
+51,653
New +$409K
MDNA
21
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$383K 0.07%
+92,453
New +$372K
ADAP
22
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-781,940
Closed -$7.83M
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-1,057,827
Closed -$8.55M
ETNB
24
DELISTED
89bio
ETNB
– –
-291,140
Closed -$5.8M
VXRT
25
DELISTED
Vaxart
VXRT
– –
-2,765,000
Closed -$24.5M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2020 Portfolio in Review

As of Q3 2020, VR Adviser held 29 positions worth $511M, up 22% from $418M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

VR Adviser deployed $56.7M of net new capital in Q3 2020, opening 13 new positions and adding to 1 existing holding. Its largest new stake was LeonaBio Inc: 152,162 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Marinus Pharmaceuticals, Inc, an estimated $2.06M trimmed.

  • VR Adviser's largest Q3 2020 buy was LeonaBio Inc: 152,162 shares worth $28.1M.
  • VR Adviser added most to Trillium Therapeutics Inc. in Q3 2020, an estimated $4.13M increase.
  • VR Adviser's biggest Q3 2020 reduction was Marinus Pharmaceuticals, Inc, cutting an estimated $2.06M.
  • VR Adviser fully exited Vaxart in Q3 2020, selling an estimated $24.5M.
  • VR Adviser's ten largest holdings make up 80% of its $511M portfolio in Q3 2020.
  • VR Adviser opened 13 new positions and closed 7 in Q3 2020.
  • VR Adviser's portfolio value rose 22% quarter-over-quarter to $511M.

Based on VR Adviser's 13F filing for Q3 2020, filed 16 Nov 2020.